Back

Undertreated hypertension: a major factor in intracranial haemorrhage-related mortality in anticoagulated patients with atrial fibrillation

1 April 2025 (08:00 - 14:15)
Organised by: Logo
Congress Presentation Part of: Poster session 3: clinical management of arrhythmias Clinical EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Zehra Kadani

Darent Valley Hospital, Dartford (United Kingdom of Great Britain & Northern Ireland)

139 More presentations in this session

Presentation thumbnail
The relationship between left atrial electroanatomical voltage mapping and CMR-based fibrosis for enhanced preplanning in atrial fibrillation ablation
Doctor Z. Dadon (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Cardiac sympathetic denervation for different cardiovascular indications - the experience of two referral centers
Doctor A. Zienciuk-Krajka (Gdansk, PL)
Abstract
Presentation thumbnail
Practicing physicians perception of feasibility and usefulness of quality indicators of treatment for atrial fibrillation
Doctor J. Simic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Risk of left atrial thrombus in patients undergoing catheter ablation for atrial fibrillation and atrial flutter
Assistant Professor F. Guerra (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Clustering analysis of left atrial smax patterns: predicting atrial fibrillation termination and associations with key clinical factors
Mr J. Huh (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3: clinical management of arrhythmias

The Event

Event poster

EHRA 2025

1 April 2025 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of left atrial appendage closure on events after intracranial haemorrhage in anticoagulated patients with atrial fibrillation: real life data from the PERSEO registry
thumbnail
Congress Presentation
Impact of frailty on antihypertensive treatment in older adults
thumbnail
Congress Presentation
One-year outcomes of inappropriate DOAC dosing in patients with atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources